Rocket Pharmaceuticals Files 8-K: Operations, Personnel Changes
Ticker: RCKTW · Form: 8-K · Filed: Aug 7, 2025 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | 8-K |
| Filed Date | Aug 7, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, personnel, financials
TL;DR
Rocket Pharma 8-K dropped: financials, exec changes, director elections. Check it.
AI Summary
Rocket Pharmaceuticals, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition as of August 4, 2025. The filing also disclosed the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with details on compensatory arrangements. Additionally, it included financial statements and exhibits.
Why It Matters
This filing provides crucial updates on Rocket Pharmaceuticals' financial health and leadership structure, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — The filing covers operational results and significant personnel changes, which can introduce uncertainty or signal strategic shifts.
Key Players & Entities
- Rocket Pharmaceuticals, Inc. (company) — Registrant
- August 4, 2025 (date) — Date of earliest event reported
- August 7, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 001-36829 (filing_number) — SEC File Number
- 9 Cedarbrook Drive, Cranbury, NJ 08512 (address) — Principal executive offices
- 646-440-9100 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are being reported for the period ending August 4, 2025?
The filing indicates that Item 2.02 (Results of Operations and Financial Condition) is being reported, but the specific financial details are not provided in this summary.
Who are the directors or officers that have departed or been elected/appointed?
The filing states that Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) is being addressed, but the names of the individuals are not specified in this summary.
What are the key exhibits included with this 8-K filing?
The filing lists Item 9.01 (Financial Statements and Exhibits) as being included, but the specific exhibits are not detailed in this summary.
What is the former name of Rocket Pharmaceuticals, Inc. and when did the name change occur?
The former company name was INOTEK PHARMACEUTICALS CORP, and the date of the name change was February 26, 2004.
What is the Standard Industrial Classification (SIC) code for Rocket Pharmaceuticals, Inc. and what does it represent?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-08-07 16:02:20
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
Filing Documents
- ef20053509_8k.htm (8-K) — 30KB
- ef20053509_ex99-1.htm (EX-99.1) — 119KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-25-029582.txt ( ) — 292KB
- rckt-20250804.xsd (EX-101.SCH) — 4KB
- rckt-20250804_lab.xml (EX-101.LAB) — 21KB
- rckt-20250804_pre.xml (EX-101.PRE) — 16KB
- ef20053509_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On August 7, 2025, Rocket Pharmaceuticals, Inc. (the "Company") announced certain preliminary financial information for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective December 31, 2025, Dr. Kinnari Patel will be leaving the Company to accept a role as a venture partner at RTW Investments LP. As of August 8, 2025, Dr. Patel will no longer serve in the role as President, Head of Research and Development and will assist in transitioning her duties to other executives at the Company.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of Rocket Pharmaceuticals, Inc. dated August 7, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: August 7, 2025 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP